Zentalis Pharmaceuticals (NASDAQ:ZNTL) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report published on Monday morning, Benzinga reports. The firm currently has a $20.00 price target on the stock.

Several other research analysts have also recently commented on the stock. Oppenheimer reduced their target price on shares of Zentalis Pharmaceuticals from $50.00 to $25.00 and set an outperform rating for the company in a report on Tuesday, June 18th. Jefferies Financial Group restated a hold rating and set a $6.00 target price (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. UBS Group cut shares of Zentalis Pharmaceuticals from a buy rating to a neutral rating and reduced their target price for the stock from $28.00 to $5.00 in a report on Thursday, June 20th. Stifel Nicolaus reduced their target price on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a buy rating for the company in a report on Tuesday, June 18th. Finally, Wells Fargo & Company lowered shares of Zentalis Pharmaceuticals from an overweight rating to an equal weight rating and dropped their price target for the stock from $29.00 to $9.00 in a research report on Tuesday, June 18th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Hold and a consensus target price of $11.33.

Zentalis Pharmaceuticals Stock Down 4.5 %

Zentalis Pharmaceuticals stock opened at $2.90 on Monday. The stock has a market capitalization of $205.62 million, a PE ratio of -0.87 and a beta of 1.70. Zentalis Pharmaceuticals has a twelve month low of $2.83 and a twelve month high of $28.47. The company has a 50 day moving average of $4.88 and a 200-day moving average of $10.17.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Friday, August 9th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same quarter in the prior year, the business posted ($1.85) EPS. Equities analysts anticipate that Zentalis Pharmaceuticals will post -2.72 EPS for the current fiscal year.

Insider Activity

In other news, CFO Cam Gallagher sold 9,597 shares of the stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the transaction, the chief financial officer now directly owns 633,680 shares of the company’s stock, valued at $7,591,486.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Large investors have recently modified their holdings of the stock. Quest Partners LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at about $38,000. Tower Research Capital LLC TRC increased its position in Zentalis Pharmaceuticals by 252.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock worth $55,000 after acquiring an additional 2,589 shares during the period. Anfield Capital Management LLC bought a new position in Zentalis Pharmaceuticals during the second quarter worth about $40,000. 49 Wealth Management LLC bought a new position in Zentalis Pharmaceuticals during the first quarter worth about $172,000. Finally, Kennedy Capital Management LLC bought a new position in Zentalis Pharmaceuticals during the first quarter worth about $189,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.